================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JULY 1, 2005 (JULY 1, 2005)
MYLAN LABORATORIES INC.
(Exact name of registrant as specified in its charter)
PENNSYLVANIA 1-9114 25-1211621
(State or other jurisdiction of (Commission File (I.R.S. Employer
Incorporation) Number) Identification No.)
1500 CORPORATE DRIVE
CANONSBURG, PA 15317
(Address of principal executive offices)
(724) 514-1800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4 (c))
================================================================================
ITEM 7.01 - REGULATION FD DISCLOSURE.
In connection with presentations being made relating to the financing of the
previously announced self tender offer by Mylan Laboratories Inc., certain
information attached hereto as Exhibit 99.1 is being provided to potential
investors.
Pursuant to the rules and regulations of the Securities and Exchange Commission,
the exhibits and the information set forth therein and herein are furnished to
the Commission and shall not be deemed to be "filed" for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that Section. The information in this Current Report shall
not be incorporated by reference into any registration statement pursuant to the
Securities Act of 1933, as amended.
ITEM 9.01 - FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit No. Description
99.1 Summary Historical and Pro Forma Financial Data
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
MYLAN LABORATORIES INC.
Date: July 1, 2005 By: /s/ Edward J. Borkowski
------------------------------
Edward J. Borkowski
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
99.1 Summary Historical and Pro Forma Financial Data